Learn
GLP-1 Learning Hub
Curated articles, videos, and research — AI-summarized so you get the key insights fast.
Original
Gila·5/9/2026
Retatrutide vs Tirzepatide: The Reta Hype, Tested (2026)
🚀 **Next-Gen GLP-1 Alert!** Lilly's investigational triple-agonist, Retatrutide, is showing jaw-dropping ~24% weight loss in trials, potentially outpacing Tirzepatide! While the numbers are exciting and hint at the future, remember this crucial truth: the real, lasting success on *any* medication comes from building those rock-solid habits that support you long-term, because sustained results are about more than just the scale.
Read more →
Original
Gila·5/9/2026
Foundayo vs Wegovy vs Zepbound: The 2026 Oral GLP-1 Decision Guide
💊 **Oral GLP-1 Game Changer!** Get ready for an exciting new landscape in oral GLP-1s! Our latest update reveals Foundayo (orforglipron) as the ultimate winner for convenience, offering the first daily pill with absolutely no food or water restrictions, making adherence a breeze. While injectable Zepbound still leads for maximum weight loss, we now have amazing new options to consider based on your lifestyle, desired weight loss, and budget, proving your journey is more personalized than ever.
Read more →
Article
Gila·4/30/2026
Compounded GLP-1s in 2026: What FDA's April 30 Proposal Means for 503B and 503A Patients
🚨 **Heads Up, Team!** The FDA just proposed changes that could impact compounded GLP-1 access from 503B facilities by 2026. This isn't immediate, but it's a call to action: connect with your prescriber now to proactively plan your transition to approved medications, ensuring your incredible progress continues seamlessly. Remember, your habits are your superpower, and we'll navigate any shifts together!
Read more →
Article
Gila·4/27/2026
GLP-1 Adherence Statistics 2026: Why Persistence Nearly Doubled
12-month persistence on weight-loss GLP-1s climbed from 33% in 2021 to 63% in 2024. Inside the latest Prime Therapeutics, KFF, and NEJM data — what the new numbers actually say about who stays on therapy, who stops, and why.
Read more →
Original
Gila·4/24/2026
The Best Free GLP-1 Tracker Apps for iPhone in 2026
Most free GLP-1 apps are freemium — the essentials are free but the useful stuff hides behind a paywall. A few are genuinely free. Here are the best free and meaningfully free GLP-1 tracker apps for iPhone in 2026, plus what still is not worth paying for.
Read more →
Article
Gila·4/24/2026
The Hidden GLP-1 Side Effects Clinical Trials Missed (Penn Study)
🩺 **Your Symptoms ARE Validated!** A groundbreaking Penn study used AI to analyze over 400,000 Reddit posts, uncovering GLP-1 side effects like irregular cycles and temperature changes that clinical trials often miss. This incredible research validates that if you're experiencing something "different," you're not alone, and your unique journey is helping us understand these medications even better!
Read more →
Article
Gila·4/18/2026
Mounjaro vs Ozempic vs Zepbound vs Wegovy (2026): The Honest Comparison
Four drugs, two active ingredients. Tirzepatide (Mounjaro/Zepbound) produces ~21% weight loss; semaglutide (Ozempic/Wegovy) ~15%. A clinically-honest breakdown across efficacy, side effects, cost, insurance, availability, and the lived experience — plus which one is probably right for you.
Read more →
Article
Gila·4/18/2026
Zepbound Side Effects Month-by-Month: The Real Timeline From Clinical Data
Most Zepbound side effects peak during dose escalation and fade within 2-4 weeks at each stable dose. Here is the month-by-month timeline from SURMOUNT clinical data — what to expect at 2.5mg, 5mg, 7.5mg, and higher doses, plus when to call your prescriber.
Read more →
Article
Gila·4/18/2026
Restarting Your GLP-1 After Quitting: What the 2026 Research Actually Says
🔄 **Restarting Your GLP-1? It's a Smart Reset!** New research reveals many people pause their GLP-1 journey, making restarting a common and powerful decision. This isn't a setback; it's an opportunity to learn from your initial experience and strategically recalibrate with your prescriber for durable, long-term success. Think of it as a new, informed chapter in your health journey!
Read more →
Article
Gila·4/18/2026
You're Not Broken: Why GLP-1s Don't Work for 1 in 10 People (2026 Research)
✨ **Your Body's Unique!** Game-changing research just dropped, showing that about 1 in 10 people carry genetic variants making GLP-1s less effective for them. This means if your medication isn't hitting as hard as expected, it's not your fault – it's fascinating biology, and precision medicine is on the horizon!
Read more →
Article
Gila·4/13/2026
Ozempic Not Working Anymore? Why Your Medication Feels Different After Months
If you are 6 to 9 months into Ozempic and the medication has started feeling less effective, you are not imagining it and you are not broken. Three causes account for most of these reports: metabolic recalibration as your body adjusts to a smaller mass, behavioral drift as appetite habits quietly rebuild around the medication, and dropping cumulative serum exposure from missed or late doses. Here is what to actually check before escalating dose or switching to Mounjaro or Zepbound.
Read more →
Article
Gila·4/13/2026
GLP-1 vs Intermittent Fasting: Why Stacking Them Backfires (2026 Research)
Intermittent fasting alone produces 1-3% weight loss in trials. GLP-1 medications produce 15-22%. Stacking them rarely accelerates results and often increases muscle-loss risk. Here is what the 2026 research actually shows, why the food-noise paradox matters, and what to focus on instead.
Read more →
Article
Gila·4/8/2026
I Tested 8 GLP-1 Tracker Apps. Only Two Actually Build Habits.
Tested 8 GLP-1 tracker apps for 2026: Shotsy, MeAgain, Pep, GlucoPal, Healthi, DreamMe, Pokii, GLP Buddy. Most are pure logs — only two help you build habits. Free vs paid, iPhone picks, and a 12-question FAQ from real GLP-1 user search behavior.
Read more →
Original
Gila·4/6/2026
$14 a Month Semaglutide Is Real. Why You Probably Still Cannot Get It.
Generic semaglutide launched in India at $14/month on March 20, 2026. Foundayo entered the US at $149/month. Medicare added obesity coverage via the BALANCE Model. Here is what generic GLP-1 access actually means in 2026 — and why US generic Ozempic is still 5+ years away.
Read more →
Original
Gila·4/6/2026
Wegovy HD Approved: What the Higher 7.2mg Dose Means for Your Journey
The FDA approved Wegovy HD (semaglutide 7.2mg) on March 19, 2026. The STEP UP trial showed 20.7% mean weight loss vs 17.5% with standard 2.4mg. Designed for adults already tolerating the standard dose who need additional weight reduction. Available April 2026 as a single-dose pen.
Read more →
Original
Gila·4/6/2026
GLP-1 Medications May Reduce Depression and Anxiety: What the New Research Shows
A major 2026 Lancet Psychiatry study of 100,000 people found GLP-1 medications reduced depression risk by 44% and anxiety by 38%. The within-individual study design compared the same patients on and off treatment, revealing significant mental health benefits including 42% fewer psychiatric hospitalizations and 47% lower substance use disorders.
Read more →
Original
Gila·4/6/2026
Are Your GLP-1 Habits Strong Enough? Take This Free Self-Assessment
A free 10-question self-reflection quiz to explore how strong your daily habits are on your GLP-1 journey. Not a clinical test — a gentle mirror for where you are and where to focus next.
Read more →
Original
Gila·4/6/2026
Stopping Ozempic Cold Turkey: What the Research Actually Says (2026)
Thinking about stopping your GLP-1 medication abruptly? Research shows 67% of weight is regained within 12 months. Here is what happens to your body and how to taper safely.
Read more →
Original
Gila·4/6/2026
Orforglipron Approved: Lilly's GLP-1 Pill Is Here — What It Means for Your Journey
The FDA approved orforglipron — Eli Lilly's once-daily GLP-1 pill — on April 1, 2026. No injections needed. Here's what it means for people on or considering GLP-1 medications.
Read more →
Original
Gila·4/6/2026
Zepbound Savings Card: Complete Guide to Eligibility, Discounts, and How to Save in 2026
Everything you need to know about the Zepbound savings card in 2026 — eligibility requirements, how much you can save, how to apply, and what to do if you don't qualify.
Read more →
Original
Gila·3/30/2026
GLP-1 Prices Just Collapsed. Here is What You Will Actually Pay in 2026.
GLP-1 list prices fell 50% in 12 months. Oral Wegovy launched at $675/month vs $1,349 injection. Foundayo entered at $149/month. Indian generics hit $14/month. Here is the full 2026 cost landscape and what each path actually costs you.
Read more →
Original
Gila·3/30/2026
400,000 People Took the Wegovy Pill in 10 Weeks. Here Is What That Means for You.
Novo Nordisk reports 400,000 Americans started oral Wegovy in 10 weeks — the fastest US drug launch in history. At $675/month list price (50% below the injection) and $499 with the savings card, the pill broke the cost barrier for first-time patients. Here is what the launch reveals and what it means for your access.
Read more →
Original
Gila·3/30/2026
GLP-1 Gastroparesis: What the Research Actually Says About Stomach Paralysis Risk
GLP-1 gastroparesis risk explained with real data. The JAMA study found a 3.67x increased risk — here's what that actually means for you, who's most at risk, and what to watch for.
Read more →
Article
Gila·3/22/2026
Oral GLP-1 Pills Are Here: What You Need to Know
FDA approved the first oral GLP-1 pill for weight loss. Compare pills vs injections — efficacy, convenience, cost, and who they work best for.
Read more →